Category: DMD Treatment and Therapeutic Approaches
Utrophin
In Duchenne Muscular Dystrophy (DMD), utrophin acts as a natural structural surrogate or "backup" protein that can functionally compensate for the lack of dystrophin. It is one of the most promising targets for mutation-independent therapeutic development.
When a person has DMD and cannot produce functional dystrophin, the body recognizes the structural deficit and naturally tries to compensate. • Up-regulation and Redistribution: In DMD patients (and the mdx mouse model), utrophin expression is naturally "switched back on" or up-regulated. It leaves its restricted post-natal zone (the NMJ) and redistributes along the entire sarcolemma (the muscle membrane) where dystrophin should have been. • Functional Mimicry: Because utrophin contains similar binding properties, it attempts to link the internal actin cytoskeleton to the DGC just like dystrophin does. • The Catch: While this natural up-regulation helps slow down early disease progression, the default levels of utrophin produced by the body in adulthood are simply too low to fully counteract the severe, continuous muscle damage of Duchenne.
- Abbreviation:
- Paralogue of Dystrophin
- Updated November 4, 2026